Close Menu

NEW YORK (360Dx) – French in vitro diagnostics firm Theradiag said on Monday that it has reached a deal with Immunodiagnostic Systems allowing access to that company's IDS-i10 automation system.

Under the terms of the deal, Theradiag is launching its Tracker biotherapy monitoring product line on the IDS-i10 system, it said, adding it has created a new commercial development program for Tracker tests to be based on the IDS technology. Tracker tests allow clinicians to monitor and optimize biotherapies treatments.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.